These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 15482632)

  • 1. The many faces of fatigue in major depressive disorder.
    Demyttenaere K; De Fruyt J; Stahl SM
    Int J Neuropsychopharmacol; 2005 Mar; 8(1):93-105. PubMed ID: 15482632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatigue as a core symptom in major depressive disorder: overview and the role of bupropion.
    Pae CU; Lim HK; Han C; Patkar AA; Steffens DC; Masand PS; Lee C
    Expert Rev Neurother; 2007 Oct; 7(10):1251-63. PubMed ID: 17939764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptoms of fatigue and sleepiness in major depressive disorder.
    Baldwin DS; Papakostas GI
    J Clin Psychiatry; 2006; 67 Suppl 6():9-15. PubMed ID: 16848671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine.
    Sarfati D; Evans VC; Tam EM; Woo C; Iverson GL; Yatham LN; Lam RW
    Int Clin Psychopharmacol; 2017 Nov; 32(6):343-349. PubMed ID: 28763344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine. Fibromyalgia, chronic fatigue syndrome, migraine, irritable bowel syndrome, atypical facial pain, and premenstrual dysphoric disorder.
    Gruber AJ; Hudson JI; Pope HG
    Psychiatr Clin North Am; 1996 Jun; 19(2):351-69. PubMed ID: 8827194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder.
    Stahl SM; Zhang L; Damatarca C; Grady M
    J Clin Psychiatry; 2003; 64 Suppl 14():6-17. PubMed ID: 14658930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Modafinil in the treatment of depression].
    Videbech P
    Ugeskr Laeger; 2012 Feb; 174(6):348-51. PubMed ID: 22310006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modafinil use in patients with a primary psychiatric illness.
    Black W; Hoey P; Mayze T
    Aust N Z J Psychiatry; 2010 Jun; 44(6):583-4. PubMed ID: 20482418
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacological approaches to the treatment of residual symptoms.
    Fava M
    J Psychopharmacol; 2006 May; 20(3 Suppl):29-34. PubMed ID: 16644769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
    Akiskal HS; Benazzi F; Perugi G; Rihmer Z
    J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
    Hantouche EG; Akiskal HS; Lancrenon S; Chatenêt-Duchêne L
    J Affect Disord; 2005 Feb; 84(2-3):243-9. PubMed ID: 15708422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of response to adjunctive osmotic-release methylphenidate or placebo in patients with major depressive disorder: effects of apathy/anhedonia and fatigue.
    Rizvi SJ; Geraci J; Ravindran A; Kennedy SH
    J Clin Psychopharmacol; 2014 Dec; 34(6):755-9. PubMed ID: 25203470
    [No Abstract]   [Full Text] [Related]  

  • 13. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
    Mouchabac S; Ferreri M; Cabanac F; Bitton M
    Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major depression and somatic symptoms in a mind/body medicine clinic.
    Nakao M; Yamanaka G; Kuboki T
    Psychopathology; 2001; 34(5):230-5. PubMed ID: 11799317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The many different faces of major depression: it is time for personalized medicine.
    Korte SM; Prins J; Krajnc AM; Hendriksen H; Oosting RS; Westphal KG; Korte-Bouws GA; Olivier B
    Eur J Pharmacol; 2015 Apr; 753():88-104. PubMed ID: 25592320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
    Thomas SJ; Shin M; McInnis MG; Bostwick JR
    Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective trial of modafinil as an adjunctive treatment of major depression.
    DeBattista C; Lembke A; Solvason HB; Ghebremichael R; Poirier J
    J Clin Psychopharmacol; 2004 Feb; 24(1):87-90. PubMed ID: 14709953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major depression and its response to sertraline in primary care vs. psychiatric office practice patients. Results of an open-label trial in Argentina.
    Lyketsos CG; Taragano F; Treisman GJ; Paz J
    Psychosomatics; 1999; 40(1):70-5. PubMed ID: 9989124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.